A trial to assess the safety of nebulised heparin for acute lung injury
Phase 1
- Conditions
- Acute lung injuryRespiratory - Other injuries and accidents
- Registration Number
- ACTRN12606000388516
- Lead Sponsor
- St Vincents Health Melboune
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Acute lung injurymechanical ventilation.
Exclusion Criteria
Systemic heparin administrationPulmonary haemorrhage.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety[All measured 1 hour after the nebulised drug is given.];Bleeding[All measured 1 hour after the nebulised drug is given.];Activated partial thromboplastin time[All measured 1 hour after the nebulised drug is given.]
- Secondary Outcome Measures
Name Time Method Alveolar dead space[Measured one hour after each episode of the nebulised drug.]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie nebulized heparin's anti-inflammatory effects in acute lung injury?
How does nebulized heparin compare to standard anticoagulants in managing ARDS-related coagulopathy?
Which biomarkers correlate with improved oxygenation in nebulized heparin-treated acute lung injury patients?
What pulmonary adverse events are associated with nebulized heparin in phase I trials for lung injury?
Are there synergistic effects of combining nebulized heparin with surfactant therapy in acute respiratory distress syndrome?